Noxxon Pharma Raises Series C

Noxxon Pharma AG, a Berlin, Germany-based developer of biostable aptamers, has raised EUR 37 million in Series C funding. New backers included TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure, Dow Venture Capital, IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH and VC Fonds Berlin GmbH. Returning shareholders included Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG (DEWB), FCP OP Medical BioHealth-Trends and the Dieckell Group. www.noxxon.net